Press Releases

Accelero contributes tp CombiGene AB’s Gene Therapy Program for Epilepsy

Accelero is proud becoming a selected partner for the leading Nordic gene therapy company CombiGene AB (Lund) developing an AAV-based treatment targeting epilepsy.

Main purpose of the bioanalytical study package is the GLP compliant biodistribution and shedding analysis in cooperation with the CG01 project partner Northern Biomedical Research Inc. (Norton Shores, MI, United States). This includes  immunogenicity testing of the vector and its expression products.

Accelero will also be responsible for the sample import from North America into the European Union. All assays will be fully validated in compliance with the respective EMA and FDA guidelines for bioanalytical method validation.

Please feel free to follow this link for the complete CombiGene press release.